Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SHBG | P04278 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277500 | 0.88 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL19692162 | 0.88 | CA2 (0.36) | MAOBCA2NR3C1KMT2AALDH1A1 | |
| SCHEMBL18706282 | 0.84 | ALDH1A1 (0.42) | MEN1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL2325728 | 0.84 | KCNH2 (0.33) | — | |
| SCHEMBL1559901 | 0.84 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1TDP1HTT | |
| SCHEMBL16337448 | 0.81 | PDCD1 (0.39) | HTTTSHRMAPK1 | |
| SCHEMBL18580455 | 0.81 | ALDH1A1 (0.46) | RAB9ATRIM24ALDH1A1HPGDTDP1 | |
| SCHEMBL17112790 | 0.80 | HSD17B1 (0.34) | SHBG | |
| SCHEMBL15569698 | 0.80 | TSHR (0.36) | CA2TSHR | |
| SCHEMBL473910 | 0.79 | KDM4E (0.37) | CA2MEN1RAB9AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405136-A1 | New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration | CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED, M.P. (ES) | 2023-12-21 | — | — | US | claimed |
| EP-4221758-A1 | NEW COMBINATIONS OF BORON COMPOUNDS AND ADJUVANTS FOR THE TREATMENT OF PATHOPHYSIOLOGICAL CONDITIONS AND CANCER AND FOR MUSCLE REGENERATION | Consorcio Centro de Investigación Biomédica en Red M.P. (ES) | 2023-08-09 | — | — | EP | claimed |
| WO-2022069768-A1 | NEW COMBINATIONS OF BORON COMPOUNDS AND ADJUVANTS FOR THE TREATMENT OF PATHOPHYSIOLOGICAL CONDITIONS AND CANCER AND FOR MUSCLE REGENERATION | Consorcio Centro de Investigación Biomédica en Red, M.P. (ES) | 2022-04-07 | — | — | WO | claimed |
| EP-3978028-A1 | NEW COMBINATIONS OF BORON COMPOUNDS AND ADJUVANTS FOR THE TREATMENT OF PATHOPHYSIOLOGICAL CONDITIONS AND MUSCLE REGENERATION | Consorcio Centro de Investigación Biomédica en Red M.P. (ES) | 2022-04-06 | — | — | EP | claimed |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4587126-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-07-23 | — | — | EP | disclosed |
| CN-118344367-A | 1, 6-Disubstituted pyrazolo [3,4-d ] pyrimidine compound and preparation method and application thereof | 复旦大学 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024057021-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| US-20230405136-A1 | New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration | CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED, M.P. (ES) | 2023-12-21 | — | — | US | disclosed |
| EP-4221758-A1 | NEW COMBINATIONS OF BORON COMPOUNDS AND ADJUVANTS FOR THE TREATMENT OF PATHOPHYSIOLOGICAL CONDITIONS AND CANCER AND FOR MUSCLE REGENERATION | Consorcio Centro de Investigación Biomédica en Red M.P. (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4041724-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2183027-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-05-12 | — | — | EP | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009013335-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BRD9, BRD2, BRD1 | MAOB 286/4885CA2 2221/4885NR3C1 1860/4885 |
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | MAOB 1721/4885CA2 785/4885NR3C1 138/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | MAOB 3364/4885CA2 4203/4885NR3C1 2447/4885 |
| US-20230405136-A1 | New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration | MUSK, MBNL1, MYOF | MAOB 4362/4885CA2 980/4885NR3C1 294/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | MAOB 1310/4885CA2 3768/4885NR3C1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.